Brief: Coya Therapeutics Announces U.S. FDA Acceptance Of Investigational New Drug Application For COYA 302
05/01/2026 14:00
Jan 5 (Reuters) - Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS ANNOUNCES U.S. FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR COYA 302 FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA (FTD) COYA THERAPEUTICS ANNOUNCES U.S. FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR COYA 302 FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA (FTD) Source text: ID:nBwkm0Fra Further company coverage: COYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)